Aflatoxin exposure in pregnant women of mixed status of human immunodeficiency virus infection and rate of gestational weight gain: a Ugandan cohort study.


Journal

Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 6 7 2020
medline: 9 3 2021
entrez: 6 7 2020
Statut: ppublish

Résumé

To examine the association between aflatoxin (AF) exposure during pregnancy and rate of gestational weight gain (GWG) in a sample of pregnant women of mixed HIV status in Gulu, northern Uganda. 403 pregnant women were included (133 HIV-infected on antiretroviral therapy (ART), 270 HIV-uninfected). Women's weight, height and socio-demographic characteristics were collected at baseline (~19 weeks' gestation); weight was assessed at each follow-up visit. Serum was collected at baseline and tested for aflatoxin B AFB-lys levels (detected in 98.3% of samples) were higher among HIV-infected pregnant women than HIV-uninfected pregnant women [median (interquartile range): 4.8 (2.0, 15.0) vs. 3.5 (1.6, 6.1) pg/mg of albumin, P < 0.0001]. Adjusting for HIV status, a one-log increase in aflatoxin levels was associated with a 16.2 g per week lower rate of GWG (P = 0.028). The association between AFB-lys and the rate of GWG was stronger and significant only among HIV-infected women on ART [-25.7 g per week per log (AFB-lys), P = 0.009 for HIV-infected women vs. -7.5 g per week per log (AFB-lys), P = 0.422 for HIV-uninfected women]. Pregnant women with higher levels of AF exposure had lower rates of GWG. The association was stronger for HIV-infected women on ART, suggesting increased risk. Examiner l'association entre l'exposition à l'aflatoxine (AF) pendant la grossesse et le taux de gain de poids pendant la grossesse (GWG) dans un échantillon de femmes enceintes de statut mixte VIH à Gulu, dans le nord de l' Ouganda. MÉTHODES: 403 femmes enceintes ont été incluses (133 infectées par le VIH sous traitement antirétroviral (ART), 270 non infectées par le VIH). Le poids, la taille et les caractéristiques sociodémographiques des femmes ont été collectés au départ (~19 semaines de gestation); le poids a été évalué à chaque visite de suivi. Le sérum a été recueilli au départ et testé pour les niveaux d'adduit d'aflatoxine B Les femmes enceintes présentant des niveaux plus élevés d'exposition à l’AF avaient des taux de GWG plus faibles. L'association était plus forte pour les femmes infectées par le VIH sous ART, ce qui suggère un risque accru.

Autres résumés

Type: Publisher (fre)
Examiner l'association entre l'exposition à l'aflatoxine (AF) pendant la grossesse et le taux de gain de poids pendant la grossesse (GWG) dans un échantillon de femmes enceintes de statut mixte VIH à Gulu, dans le nord de l' Ouganda. MÉTHODES: 403 femmes enceintes ont été incluses (133 infectées par le VIH sous traitement antirétroviral (ART), 270 non infectées par le VIH). Le poids, la taille et les caractéristiques sociodémographiques des femmes ont été collectés au départ (~19 semaines de gestation); le poids a été évalué à chaque visite de suivi. Le sérum a été recueilli au départ et testé pour les niveaux d'adduit d'aflatoxine B

Identifiants

pubmed: 32623795
doi: 10.1111/tmi.13457
pmc: PMC7539974
doi:

Substances chimiques

Aflatoxins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1145-1154

Informations de copyright

© 2020 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd.

Références

Int Immunol. 2005 Jun;17(6):807-14
pubmed: 15944194
PLoS One. 2018 Oct 23;13(10):e0206035
pubmed: 30352100
Mutat Res. 1999 Mar 8;424(1-2):167-81
pubmed: 10064859
Toxicol Sci. 2010 Jan;113(1):216-25
pubmed: 19875679
BMC Psychiatry. 2014 Nov 22;14:303
pubmed: 25416286
Am J Trop Med Hyg. 2017 Apr;96(4):770-776
pubmed: 28500823
BMC Public Health. 2018 Nov 09;18(1):1247
pubmed: 30413157
Environ Health Perspect. 2010 Jun;118(6):818-24
pubmed: 20172840
J Health Popul Nutr. 2013 Dec;31(4):435-45
pubmed: 24592584
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011 Sep;28(9):1224-34
pubmed: 21749228
Carcinogenesis. 1990 Jun;11(6):1033-5
pubmed: 2112058
Food Chem Toxicol. 2014 Dec;74:184-9
pubmed: 25308602
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1653-7
pubmed: 18628416
Future Microbiol. 2014;9(2):121-4
pubmed: 24571065
Ann Trop Paediatr. 2002 Mar;22(1):3-9
pubmed: 11926047
J Nutr. 2019 Oct 1;149(10):1818-1825
pubmed: 31198947
Environ Health Perspect. 2004 Sep;112(13):1334-8
pubmed: 15345349
Biochem J. 1967 Apr;103(1):258-61
pubmed: 6033768
Obes Rev. 2008 Mar;9(2):140-50
pubmed: 18221480
Am J Obstet Gynecol. 2002 Dec;187(6):1660-6
pubmed: 12501080
Toxicology. 2001 Oct 15;167(2):101-34
pubmed: 11567776
Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):343-51
pubmed: 15617020
Int J Cancer. 2015 Mar 15;136(6):1254-62
pubmed: 25070670
Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1:285-301
pubmed: 22742616
Public Health Nutr. 2015 Nov;18(16):2895-905
pubmed: 25171462
Demography. 2001 Feb;38(1):115-32
pubmed: 11227840
Acta Paediatr Scand. 1989 May;78(3):373-8
pubmed: 2741679
BMC Med. 2018 Aug 31;16(1):153
pubmed: 30165842
Toxicology. 2013 Jan 7;303:147-51
pubmed: 23146766
Matern Child Nutr. 2019 Apr;15(2):e12701
pubmed: 30242967
World Mycotoxin J. 2013;6(3):255-261
pubmed: 31534557
Crit Rev Food Sci Nutr. 2020;60(19):3321-3341
pubmed: 31694387
Am J Clin Nutr. 2004 Nov;80(5):1106-22
pubmed: 15531656
Vet Immunol Immunopathol. 1998 Apr 16;62(3):245-60
pubmed: 9643458
Clin Dev Immunol. 2008;2008:790309
pubmed: 18695741
J Toxicol Environ Health B Crit Rev. 2000 Apr-Jun;3(2):109-43
pubmed: 10834078
J Appl Toxicol. 2014 Mar;34(3):241-9
pubmed: 23508487
Trop Med Int Health. 2010 Feb;15(2):160-7
pubmed: 20003033
BMJ Open Gastroenterol. 2017 Oct 26;4(1):e000166
pubmed: 29119002
BMJ. 2002 Jul 6;325(7354):20-1
pubmed: 12098724
Crit Rev Toxicol. 2011 Oct;41(9):740-55
pubmed: 21711088
Int J Epidemiol. 2007 Oct;36(5):1119-25
pubmed: 17576701

Auteurs

Jacqueline M Lauer (JM)

Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA, USA.
Feed the Future Innovation Lab for Nutrition, Tufts University, Boston, MA, USA.

Barnabas K Natamba (BK)

MRC/UVRI and LSHTM Uganda Research Unit, Noncommunicable Diseases Theme, Entebbe, Uganda.

Shibani Ghosh (S)

Feed the Future Innovation Lab for Nutrition, Tufts University, Boston, MA, USA.
Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.

Patrick Webb (P)

Feed the Future Innovation Lab for Nutrition, Tufts University, Boston, MA, USA.
Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.

Jia-Sheng Wang (JS)

Department of Environmental Health Science, University of Georgia, Athens, GA, USA.

Jeffrey K Griffiths (JK)

Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.
Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH